Health Condition 1: M629- Disorder of muscle, unspecified
Conditions
Interventions
Intervention1: Oral Protein Supplementation: Fifty patients diagnosed with sarcopenia or at risk of developing sarcopenia will be randomly allocated to receive either oral protein supplementation and
Sponsors
Sarmini Varatharajan
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age: Participants must be aged 40 years or above. 2. Diagnosis: Individuals diagnosed with sarcopenia or deemed at risk of developing sarcopenia based on clinical assessment or screening tools. 3. Admission: Patients admitted to Saveetha Medical College Hospital for any medical condition or reason. 4. Consent: Participants must provide informed consent or have a legal guardian provide consent on their behalf.
Exclusion criteria
Exclusion criteria: 1. Age: Participants under the age of 40 years. 2. Cognitive Impairment: Patients with significant cognitive impairment that may affect their ability to provide informed consent or participate in study assessments. 3. Severe Organ Dysfunction: Individuals with severe renal impairment, hepatic dysfunction, or other significant organ dysfunction that may confound study outcomes or pose safety concerns. 4. Active Malignancy: Patients with active malignancy undergoing treatment. 5. Inability to Provide Informed Consent: Individuals unable to provide informed consent due to language barriers, communication difficulties, or other reasons. 6. Pregnancy or Lactation: Women who are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the change in muscle mass, as assessed by DEXA scan and change in serum vimentin levels, as measured by ELISA, from baseline to the two-week follow-up.Timepoint: Baseline and 2 weeks follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in muscle strength, evaluated using dynamometry, and functional status, assessed by the Barthel index, from baseline to the two-week follow-up. 2. Correlation between changes in serum vimentin levels and improvements in muscle mass, strength, and functional status. 3. Comparison of the effects of protein supplementation versus standard care on muscle mass, strength, functional status, and serum vimentin levels in the intervention and control groups. 4. Evaluation of the potential utility of vimentin as a biomarker for predicting the progression of sarcopenia and response to protein supplementation.Timepoint: Baseline and 2 weeks follow up | — |
Countries
India
Contacts
Public ContactSarmini Varatharajan
Saveetha Institute of Medical and Technical Sciences
Outcome results
None listed